Abstract
The prevalence of obesity continues to increase throughout the world in an analogous way to that of type 2 diabetes mellitus (T2DM). Excess adiposity and accompanying insulin resistance is frequently associated to the development of cardiovascular disease. The circulating hormone resistin, which is produced mainly by adipocytes and appears to be increased in obesity and inflammation, seems to play a role in this association. Some studies indicate that T2DM patients have increased circulating concentrations of resistin, although these results need further confirmation. Increased resistin concentrations have been described in patients with severe inflammatory disease. However, the precise physiological role of resistin in the pathogenesis and perpetuation of inflammation remains unclear. Resistin exerts direct effects to promote the activation of endothelial cells inducing the release of endothelin-1, increasing the expression of adhesion molecules and chemokines, and potentiating the effect of the CD40 ligand. The present review summarizes recent advances in understanding the physiology of resistin and analyzes the involvement of this hormone in inflammation and cardiovascular disease.
Keywords: resistin, inflammation, cardiovascular disease, obesity, adipose tissue, insulin resistance
Current Diabetes Reviews
Title: Evidence for the Involvement of Resistin in Inflammation and Cardiovascular Disease
Volume: 1 Issue: 3
Author(s): Javier Gomez-Ambrosi and Gema Fruhbeck
Affiliation:
Keywords: resistin, inflammation, cardiovascular disease, obesity, adipose tissue, insulin resistance
Abstract: The prevalence of obesity continues to increase throughout the world in an analogous way to that of type 2 diabetes mellitus (T2DM). Excess adiposity and accompanying insulin resistance is frequently associated to the development of cardiovascular disease. The circulating hormone resistin, which is produced mainly by adipocytes and appears to be increased in obesity and inflammation, seems to play a role in this association. Some studies indicate that T2DM patients have increased circulating concentrations of resistin, although these results need further confirmation. Increased resistin concentrations have been described in patients with severe inflammatory disease. However, the precise physiological role of resistin in the pathogenesis and perpetuation of inflammation remains unclear. Resistin exerts direct effects to promote the activation of endothelial cells inducing the release of endothelin-1, increasing the expression of adhesion molecules and chemokines, and potentiating the effect of the CD40 ligand. The present review summarizes recent advances in understanding the physiology of resistin and analyzes the involvement of this hormone in inflammation and cardiovascular disease.
Export Options
About this article
Cite this article as:
Gomez-Ambrosi Javier and Fruhbeck Gema, Evidence for the Involvement of Resistin in Inflammation and Cardiovascular Disease, Current Diabetes Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339905774574392
DOI https://dx.doi.org/10.2174/157339905774574392 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Onychomycosis and its Chemotherapy
Current Medicinal Chemistry Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design Primary and Secondary Hypertriglyceridaemia
Current Drug Targets The Role of MicroRNAs in the Pancreatic Differentiation of Pluripotent Stem Cells
MicroRNA Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Withdrawn: Alkaloidal Content, Medicinal, Properties of Peganum harmala L. (P. harmala)
Current Traditional Medicine Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?
Current Clinical Pharmacology Semi-Quantitative Ultrasonographic Evaluation of NAFLD
Current Pharmaceutical Design Editorial (Thematic Issue: Perinatal Stem Cells Patents and Applications: Regenerative Medicine, Tissue Repair, Immune Modulation)
Recent Patents on Regenerative Medicine Editorial (Thematic Issue: Natural Leads in Drug Discovery against Metabolic Disorders and their Related Infectious Diseases)
Current Topics in Medicinal Chemistry Sorghum (Sorghum bicolor) Extract Affects Plasma Lipid Metabolism and Hepatic Macrophage Infiltration in Diabetic Rats
Current Nutrition & Food Science Novel Validated RP-HPLC Method for Simultaneous Estimation of Valsartan & Gliclazide in Bulk and Dosage Forms
Current Pharmaceutical Analysis Statins and Vulnerable Plaque
Current Pharmaceutical Design Exploring the Protective Effect of ShenQi Compound on Skeletal Muscle in Diabetic Macrovasculopathy Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Current Drug Targets Mucoadhesivity Characterization of Isabgol Husk Mucilage Microspheres Crosslinked by Glutaraldehyde
Current Drug Delivery Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery